Gilead Moves On From Selonsertib, Looks To ATLAS To Map Its NASH Future
Executive Summary
Gilead detailed its Phase III failure with ASK1 inhibitor selonsertib in NASH, but anticipates finding a new regimen to take into Phase III in NASH with the ATLAS combination study data expected in December.
You may also be interested in...
Alnylam Interview: RNAi Leader Expands Into NASH, CNS And Eye Diseases
Feature article: Alnylam’s R&D leader Akshay Vaishnaw sets out plans for next-generation gene-silencing therapies.
Intercept Says Data Indicate Pruritus Worries In NASH Could Be Overstated
Patient-reported outcomes indicate patients don’t see itch as a major quality-of-life factor. Intercept also reports that adding earlier-stage patients to review of OCA shows better data on resolving NASH.
Gilead Increasingly Seems Focused On Combo Therapy In NASH
At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.